T
Thomas Danne
Researcher at Boston Children's Hospital
Publications - 11
Citations - 3592
Thomas Danne is an academic researcher from Boston Children's Hospital. The author has contributed to research in topics: Type 1 diabetes & Glycemic. The author has an hindex of 7, co-authored 11 publications receiving 1883 citations. Previous affiliations of Thomas Danne include Hannover Medical School.
Papers
More filters
Journal ArticleDOI
Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range
Tadej Battelino,Thomas Danne,Richard M. Bergenstal,Stephanie A. Amiel,Roy W. Beck,Torben Biester,Emanuele Bosi,Bruce A. Buckingham,William T. Cefalu,Kelly L. Close,Claudio Cobelli,Eyal Dassau,J. Hans DeVries,Kim C. Donaghue,Klemen Dovc,Francis J. Doyle,Satish K. Garg,George Grunberger,Simon Heller,Lutz Heinemann,Irl B. Hirsch,Roman Hovorka,Weiping Jia,Olga Kordonouri,Boris Kovatchev,Aaron J. Kowalski,Lori M. Laffel,Brian J. Levine,Alexander Mayorov,Chantal Mathieu,Helen R. Murphy,Revital Nimri,Kirsten Nørgaard,Christopher G. Parkin,Eric Renard,David Rodbard,Banshi Saboo,Desmond A. Schatz,Keaton C. Stoner,Tatsuiko Urakami,Stuart A. Weinzimer,Moshe Phillip,Moshe Phillip +42 more
TL;DR: This article summarizes the ATTD consensus recommendations for relevant aspects of CGM data utilization and reporting among the various diabetes populations.
Journal ArticleDOI
International Consensus on Use of Continuous Glucose Monitoring
Thomas Danne,Revital Nimri,Tadej Battelino,Richard M. Bergenstal,Kelly L. Close,J. Hans DeVries,Satish K. Garg,Lutz Heinemann,Irl B. Hirsch,Stephanie A. Amiel,Roy W. Beck,Emanuele Bosi,Bruce A. Buckingham,Claudio Cobelli,Eyal Dassau,Francis J. Doyle,Simon Heller,Roman Hovorka,Weiping Jia,Timothy W. Jones,Olga Kordonouri,Boris P. Kovatchev,Aaron J. Kowalski,Lori M.B. Laffel,David M. Maahs,Helen R. Murphy,Kirsten Nørgaard,Christopher G. Parkin,Eric Renard,Banshi Saboo,Mauro Scharf,William V. Tamborlane,Stuart A. Weinzimer,Moshe Phillip +33 more
TL;DR: This article summarizes the ATTD consensus recommendations and represents the current understanding of how CGM results can affect outcomes.
Journal ArticleDOI
International consensus on use of continuous glucose monitoring
Thomas Danne,Revital Nimri,Tadej Battelino,Richard M. Bergenstal,Kelly L. Close,J. Hans DeVries,Satish K. Garg,Lutz Heinemann,Irl B. Hirsch,Stephanie A. Amiel,Roy W. Beck,Emanuele Bosi,Bruce A. Buckingham,Claudio Cobelli,Eyal Dassau,Francis J. Doyle,Simon Heller,Roman Hovorka,Weiping Jia,Timothy W. Jones,Olga Kordonouri,Boris P. Kovatchev,Aaron J. Kowalski,Lori M.B. Laffel,David M. Maahs,Helen R. Murphy,Kirsten Nørgaard,Christopher G. Parkin,Eric Renard,Banshi Saboo,Mauro Scharf,William V. Tamborlane,Stuart A. Weinzimer,Moshe Phillip +33 more
TL;DR: In this article, the authors summarized the ATTD consensus recommendations and represented the current understanding of how CGM results can affect outcomes, as well as the current criteria for matching people with diabetes to the most appropriate glucose monitoring methodologies.
Journal ArticleDOI
Sotagliflozin in Combination With Optimized Insulin Therapy in Adults With Type 1 Diabetes: The North American inTandem1 Study
John B. Buse,Satish K. Garg,Julio Rosenstock,Timothy S. Bailey,Phillip Banks,Bruce W. Bode,Thomas Danne,Jake A. Kushner,Wendy Lane,Pablo Lapuerta,Darren K. McGuire,Anne L. Peters,John C. Reed,Sangeeta Sawhney,Paul Strumph +14 more
TL;DR: In a 1-year T1D study, sotagliflozin combined with optimized insulin therapy was associated with sustained HbA1c reduction, weight loss, lower insulin dose, fewer episodes of severe hypoglycemia, improved patient-reported outcomes, and more DKA relative to placebo.
Journal ArticleDOI
Improved Time in Range and Glycemic Variability With Sotagliflozin in Combination With Insulin in Adults With Type 1 Diabetes: A Pooled Analysis of 24-Week Continuous Glucose Monitoring Data From the inTandem Program
Thomas Danne,Bertrand Cariou,John B. Buse,Satish K. Garg,Julio Rosenstock,Phillip Banks,Jake A. Kushner,Darren K. McGuire,Anne L. Peters,Sangeeta Sawhney,Paul Strumph +10 more
TL;DR: Combined with optimized insulin in type 1 diabetes, sotagliflozin significantly increased glucose TIR without increasing time spent at <3.9 mmol/L and reduced PPG, thereby improving glycemic control.